S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NYSE:RVTY

Revvity (RVTY) Stock Forecast, Price & News

$110.88
+1.38 (+1.26%)
(As of 09/25/2023 ET)
Compare
Today's Range
$109.44
$111.00
50-Day Range
$106.83
$130.87
52-Week Range
$105.82
$150.17
Volume
444,786 shs
Average Volume
804,630 shs
Market Capitalization
$13.76 billion
P/E Ratio
16.95
Dividend Yield
0.25%
Price Target
$138.00

Revvity MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
24.5% Upside
$138.00 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
16.11%
From $4.78 to $5.55 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

521st out of 962 stocks

Analytical Instruments Industry

12th out of 26 stocks


RVTY stock logo

About Revvity (NYSE:RVTY) Stock

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

RVTY Price History

RVTY Stock News Headlines

What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing?
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
Barclays Keeps Their Hold Rating on Revvity (RVTY)
Revvity (RVTY) Gets a Hold from Bank of America Securities
Revvity: Q2 Earnings Snapshot
Revvity Board Declares Quarterly Dividend
See More Headlines
Receive RVTY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter.

RVTY Company Calendar

Ex-Dividend for 8/11 Dividend
7/20/2023
Last Earnings
8/01/2023
Dividend Payable
8/11/2023
Today
9/26/2023
Ex-Dividend for 11/10 Dividend
10/19/2023
Dividend Payable
11/10/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Employees
16,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$138.00
High Stock Price Forecast
$147.00
Low Stock Price Forecast
$130.00
Forecasted Upside/Downside
+24.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$569.18 million
Pretax Margin
11.34%

Debt

Sales & Book Value

Annual Sales
$3.31 billion
Cash Flow
$11.91 per share
Book Value
$58.49 per share

Miscellaneous

Free Float
123,489,000
Market Cap
$13.76 billion
Optionable
Optionable
Beta
1.08
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Prahlad R. Singh Ph.D. (Age 58)
    CEO, Pres & Director
    Comp: $3.23M
  • Mr. Maxwell Krakowiak (Age 33)
    Sr. VP & CFO
    Comp: $814.58k
  • Mr. Tajinder Vohra (Age 57)
    Sr. VP of Global Operations
    Comp: $927.24k
  • Mr. Joel S. Goldberg (Age 54)
    Sr. VP of Admin., Gen. Counsel & Sec.
    Comp: $1.29M
  • Mr. Daniel R. Tereau (Age 55)
    Sr. VP of Strategy & Bus. Devel.
    Comp: $967.97k
  • Mr. Andrew Okun (Age 53)
    VP, Chief Accounting Officer & Treasurer
  • Mr. Stephen Barr Willoughby
    Sr. VP of Investor Relations & Head of ESG
  • Mr. Robert Francis Friel (Age 67)
    Advisor
  • Ms. Miriame Victor (Age 42)
    Sr. VP & Chief Commercial Officer
  • Dr. Masoud Toloue Ph.D. (Age 42)
    Sr. VP of Diagnostics













RVTY Stock - Frequently Asked Questions

Should I buy or sell Revvity stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revvity in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVTY shares.
View RVTY analyst ratings
or view top-rated stocks.

What is Revvity's stock price forecast for 2023?

5 analysts have issued 1 year target prices for Revvity's shares. Their RVTY share price forecasts range from $130.00 to $147.00. On average, they predict the company's stock price to reach $138.00 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price.
View analysts price targets for RVTY
or view top-rated stocks among Wall Street analysts.

How have RVTY shares performed in 2023?

Revvity's stock was trading at $116.84 on January 1st, 2023. Since then, RVTY shares have decreased by 5.1% and is now trading at $110.88.
View the best growth stocks for 2023 here
.

When is Revvity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RVTY earnings forecast
.

How were Revvity's earnings last quarter?

Revvity, Inc. (NYSE:RVTY) announced its quarterly earnings results on Tuesday, August, 1st. The company reported $1.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.19 by $0.02. The company had revenue of $709.10 million for the quarter, compared to the consensus estimate of $708.61 million. Revvity had a trailing twelve-month return on equity of 9.06% and a net margin of 29.19%. The business's revenue for the quarter was down 20.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.32 earnings per share.

How often does Revvity pay dividends? What is the dividend yield for Revvity?

Revvity declared a quarterly dividend on Friday, July 21st. Investors of record on Friday, October 20th will be given a dividend of $0.07 per share on Friday, November 10th. This represents a $0.28 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date of this dividend is Thursday, October 19th.
Read our dividend analysis for RVTY
.

Is Revvity a good dividend stock?

Revvity (NYSE:RVTY) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.26%. The dividend payout ratio is 4.28%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RVTY will have a dividend payout ratio of 5.05% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RVTY.

What guidance has Revvity issued on next quarter's earnings?

Revvity issued an update on its FY 2023 earnings guidance on Tuesday, August, 1st. The company provided EPS guidance of $4.70-$4.90 for the period, compared to the consensus estimate of $4.94. The company issued revenue guidance of $2.80 billion-$2.85 billion, compared to the consensus revenue estimate of $2.91 billion.

What is Revvity's stock symbol?

Revvity trades on the New York Stock Exchange (NYSE) under the ticker symbol "RVTY."

How do I buy shares of Revvity?

Shares of RVTY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revvity's stock price today?

One share of RVTY stock can currently be purchased for approximately $110.88.

How much money does Revvity make?

Revvity (NYSE:RVTY) has a market capitalization of $13.76 billion and generates $3.31 billion in revenue each year. The company earns $569.18 million in net income (profit) each year or $6.54 on an earnings per share basis.

How many employees does Revvity have?

The company employs 16,700 workers across the globe.

How can I contact Revvity?

Revvity's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.perkinelmer.com. The company can be reached via phone at (781) 663-6900, via email at ir@perkinelmer.com, or via fax at 781-663-5985.

This page (NYSE:RVTY) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -